Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Total Non-Current Liabilities (2020 - 2022)

Caribou Biosciences has reported Total Non-Current Liabilities over the past 3 years, most recently at $72.9 million for Q4 2022.

  • Quarterly Total Non-Current Liabilities rose 33.72% to $72.9 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $72.9 million through Dec 2022, up 33.72% year-over-year, with the annual reading at $72.9 million for FY2022, 33.72% up from the prior year.
  • Total Non-Current Liabilities was $72.9 million for Q4 2022 at Caribou Biosciences, down from $74.7 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $74.7 million in Q3 2022 and troughed at $18.0 million in Q4 2020.
  • The 3-year median for Total Non-Current Liabilities is $65.1 million (2021), against an average of $60.1 million.
  • Year-over-year, Total Non-Current Liabilities soared 203.12% in 2021 and then surged 30.14% in 2022.
  • A 3-year view of Total Non-Current Liabilities shows it stood at $18.0 million in 2020, then soared by 203.12% to $54.5 million in 2021, then skyrocketed by 33.72% to $72.9 million in 2022.
  • Per Business Quant, the three most recent readings for CRBU's Total Non-Current Liabilities are $72.9 million (Q4 2022), $74.7 million (Q3 2022), and $73.5 million (Q2 2022).